Curis, Inc. (NASDAQ:CRIS) Sees Significant Growth in Short Interest

Curis, Inc. (NASDAQ:CRIS) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 179,462 shares, an increase of 160.0% from the September 15th total of 69,025 shares. Approximately 9.1% of the shares of the company are sold short. Based on an average trading volume of 176,280 shares, the short-interest ratio is presently 1.0 days.

Institutional Trading of Curis

Several hedge funds and other institutional investors have recently made changes to their positions in CRIS. Focused Wealth Management Inc acquired a new stake in shares of Curis in the 2nd quarter valued at approximately $26,000. BlackRock Inc. purchased a new stake in shares of Curis in the second quarter valued at approximately $28,000. Flputnam Investment Management Co. acquired a new position in Curis during the second quarter worth $128,000. Renaissance Technologies LLC grew its holdings in Curis by 52.2% during the first quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 125,823 shares during the period. Finally, Cable Car Capital LP acquired a new position in Curis during the second quarter worth $696,000. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Trading Down 4.2%

Shares of Curis stock traded down $0.03 during trading hours on Monday, hitting $0.64. 127,755 shares of the company were exchanged, compared to its average volume of 190,084. The business has a 50-day moving average of $1.54 and a 200-day moving average of $6.35. Curis has a 1 year low of $0.61 and a 1 year high of $33.60. The stock has a market capitalization of $1.34 million, a price-to-earnings ratio of -0.05 and a beta of 3.11.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.95) by $2.93. As a group, research analysts anticipate that Curis will post -15.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Curis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 22nd. Zacks Research upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Curis in a research report on Monday, August 17th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Curis presently has an average rating of “Hold” and an average price target of $43.00.

Curis Company Profile

Curis, Inc is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancer. The company’s research programs target biological pathways involved in tumor growth, survival and immune regulation, with the goal of addressing cancers that have limited treatment options.

Curis’ lead investigational product is emavusertib, also known as CA-4948, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The compound has been evaluated in clinical studies for hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes, as well as certain solid tumors.